Shaily Engineering Plastics Limited is a prominent India-based exporter specializing in the manufacture of high-precision injection-molded plastic components. Established in 1987 by Mike Sanghvi with an initial setup of two injection molding machines in Halol, Gujarat, Shaily was founded to address a market gap for precision-engineered plastic molded components. Today, it stands as India's largest exporter of plastic components. The company engages in the manufacture and sale of customized components made from plastic and other materials, catering to the diverse requirements of Original Equipment Manufacturers (OEMs). Shaily also offers secondary plastic operations, including vacuum metalizing, hot stamping, and ultrasonic welding. Its primary manufacturing facilities are strategically located in Savli and Halol, Vadodara, Gujarat.
Shaily Engineering Plastics operates across several key business segments, each designed to meet specific market needs and customer demands:
This segment offers a comprehensive range of technological solutions for patient-centric and self-medication injection systems. It includes the development and manufacturing of drug delivery devices, pen injectors, auto injectors, dry powder inhalers (DPIs), and specialized devices and packaging for the pharmaceutical industry. The healthcare segment has become a significant growth engine for Shaily, demonstrating robust operational performance with a 25% year-on-year revenue growth. This surge is largely attributed to a remarkable 62% increase in its Healthcare segment's contribution. The company has solidified its position as a key player in pharmaceutical device manufacturing, selling approximately 11-12 million pens in FY24, with anticipated volumes to rise to 17-18 million pens in FY25. Shaily projects 50-60% growth in the pharma-related aspects of the healthcare segment, even building on the strong performance of FY24.
The consumer segment encompasses a broad array of products, including home furnishings, FMCG packaging, LED lights, and toys. Notably, Shaily has secured new business in the Home Furnishing segment from two major global retail chains, with supplies expected to commence in Q1/Q2 FY26. The company also manufactures a range of plastic and plastic/electronic children's toys for global markets.
Shaily also serves various industrial applications through its precision manufacturing capabilities. It leverages its expertise in processing both high-performance and ultra-high-performance polymers, as well as commodity polymers in high volumes, to meet the demands of diverse industrial sectors.
Traditionally, Shaily has specialized in manufacturing plastic components from high-performance and ultra-high-performance polymers. However, the company has expanded its capabilities to process all commodity polymers in high volumes. Shaily Engineering Plastics Ltd is dedicated to providing service excellence in plastics injection molding. It is one of the few companies in the industry equipped with a Class 10000 Clean Room Injection Molding Facility, ensuring the highest standards of production for sensitive components. The company's manufacturing infrastructure is strategically situated in Gujarat, offering excellent access to key markets and supply chains. In 1994, Shaily established its second facility at Rania, Gujarat, which now serves as the company's headquarters.
For the full fiscal year ending March 2025, Shaily Engineering Plastics reported a net profit of ₹93.12 crore, marking a significant increase of 62.54% compared to ₹57.29 crore in the previous fiscal year ended March 2024. Revenue for the full year also saw substantial growth, rising by 22.20% to ₹786.80 crore in the year ended March 2025, up from ₹643.87 crore in the previous fiscal year.
In the fourth quarter (Q4 FY25) ending March 2025, the company delivered strong quarterly performance. Net profit rose by 47.83% to ₹28.59 crore, compared to ₹19.34 crore in the corresponding quarter of the previous year (Q4 FY24). Sales for Q4 FY25 increased by 27.71% to ₹217.83 crore, up from ₹170.56 crore in Q4 FY24.
- Revenue (FY25): ₹786.80 Crores
- Net Profit (FY25): ₹93.12 Crores
- Market Cap: ₹8,649.21 Crores (as of 5th June 2025)
- P/E Ratio: 92.89
- Dividend: The Board of Directors recommended a final dividend of ₹2 per equity share (100%), subject to shareholder approval.
Shaily Engineering Plastics holds a significant market position with a market capitalization of ₹8,649.21 crores as of June 5, 2025, reflecting an impressive 112% increase over the past year. Promoter holding stands at 43.7%. The company's stock has demonstrated exceptional performance, with the Shaily Engineering Plastics share price increasing by 66.37% over the last six months and a remarkable 147.32% in the past year. This robust stock performance indicates strong investor confidence in the company's growth trajectory and market standing. The 52-week high for Shaily Engineering Plastics Ltd (SHAILY) is ₹2,073.80, and the 52-week low is ₹540.75.
Shaily Engineering Plastics is actively pursuing strategic initiatives to enhance its global market reach and operational efficiency. These include the establishment of a subsidiary in Dubai and the integration of experienced talent into its workforce. While new contracts for innovative medical devices present promising growth opportunities, the company faces challenges in managing production capacity and sustaining growth rates amidst competitive pressures and market uncertainties.
The company is focused on capacity expansion to meet increasing demand, particularly in the high-growth healthcare segment. Q4 FY25 results highlighted a 22% revenue growth to INR 787 Cr, supported by a INR 150 Cr capital expenditure plan dedicated to expanding pen capacity by 40-50 million units. For its base business, Shaily anticipates a growth rate of 12% to 15%. Furthermore, businesses commercialized in Q3 and Q4 of FY24 are expected to ramp up significantly in Q2 and Q3 of FY25.
Shaily Engineering Plastics Limited represents a compelling investment opportunity within the precision plastics manufacturing sector, underpinned by strong fundamentals, diversified business segments, and a clear growth strategy that prioritizes high-value healthcare applications and global market expansion.
